Peroxisome Proliferator-Activated Receptor Alpha Is Crucial for Iloprost-Induced in vivo Angiogenesis and Vascular Endothelial Growth Factor Upregulation

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Vascular Research

• Publication date

  2008-07-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1159/000143793PMID 18617751
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical images: iloprost-induced vascular remodeling.

  2007cited by this paper
• Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension.

  2006cited by this paper
• Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.

  2005cited by this paper
• Iloprost inhalation solution for the treatment of pulmonary arterial hypertension

  2005cited by this paper
• Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors.

  2004cited by this paper
• Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

  2004cited by this paper
• Vascular Endothelial Growth Factor Is Necessary in the Development of Arteriosclerosis by Recruiting/Activating Monocytes in a Rat Model of Long-Term Inhibition of Nitric Oxide Synthesis

  2002cited by this paper
• Role of peroxisome proliferator-activated receptor alpha in epidermal development in utero.

  2002cited by this paper
• Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.

  2001cited by this paper
• Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.

  1998cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper
• A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice.

  1998cited by this paper
• Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR).

  1996cited by this paper
• The nuclear receptor superfamily: the second decade.

  1995cited by this paper
• Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

  1995cited by this paper
• cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla.

  1994cited by this paper
• [The role of iloprost in the treatment of critical ischemia of the limbs].

  1993cited by this paper

• ILOBONE: A phase I/IIa randomized controlled trial to assess the safety and feasibility of local iloprost therapy for enhancing proximal humerus fracture healing– a pilot study design

  2025cites this paper
• Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders

  2025cites this paper
• Pathophysiology of Pulmonary Arterial Hypertension: Focus on Vascular Endothelium as a Potential Therapeutic Target

  2025cites this paper
• Current Medical Therapy and Revascularization in Peripheral Artery Disease of the Lower Limbs: Impacts on Subclinical Chronic Inflammation

  2023cites this paper
• Dietary Risk Factors and Eating Behaviors in Peripheral Arterial Disease (PAD)

  2022cites this paper
• Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?

  2022cites this paper
• Principal predictors of major adverse limb events in diabetic peripheral artery disease: A narrative review

  2021cites this paper
• 2D perfusion angiography as quantitative method to evaluate iloprost effect on foot circulation.

  2021cites this paper
• Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma

  2020cites this paper
• Prostanoids for Critical Limb Ischemia: A Clinical Review and Consideration of Current Guideline Recommendations

  2019cites this paper
• Update of Key Mechanism of Hepatic Peliosis

  2019cites this paper
• VEGF synthesis is induced by prostacyclin and TGF‐β in distal lung fibroblasts from COPD patients and control subjects: Implications for pulmonary vascular remodelling

  2018cites this paper
• The angiogenic properties of human adipose-derived stem cells (HASCs) are modulated by the High mobility group box protein 1 (HMGB1).

  2017cites this paper
• Long-term clinical outcomes in critical limb ischemia--A retrospective study of 181 patients.

  2016cites this paper
• Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension

  2016cites this paper
• Prostacyclin receptors: Transcriptional regulation and novel signalling mechanisms.

  2015cites this paper
• The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors.

  2015influential citation
• Prostanoids regulate angiogenesis acting primarily on IP and EP4 receptors.

  2015influential citation
• Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells

  2015cites this paper
• New therapeutic effects of cilostazol in patients with ischemic disorders.

  2015cites this paper
• Papel del receptor alpha actitivado por proliferadores de peroxisoma en la fisiopatología del sistema cardiovascular

  2014cites this paper
• Chapter The Role of Cyclooxygenases and Lipoxygenases in the Regulation of Tumor Angiogenesis

  2013cites this paper
• Comparison of effects of iloprost and pentoxiphylline on walking capacity and skin oxygenation in diabetic patients with peripheral artery disease

  2012cites this paper
• Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner

  2012cites this paper
• Regulation of Angiogenesis in Human Cancer via Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)

  2012cites this paper
• Inhaled treprostinil for the treatment of pulmonary arterial hypertension

  2012cites this paper
• Vascular effects of prostacyclin: does activation of PPARδ play a role?

  2012cites this paper
• Cell therapy in critical limb ischemia: current developments and future progress.

  2012cites this paper
• Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1.

  2012cites this paper
• Structural Basis for Iloprost as a Dual Peroxisome Proliferator-activated Receptor α/δ Agonist*

  2011cites this paper
• [Iloprost for the treatment of digital ischaemia in pediatric septic shock].

  2011cites this paper
• Interaction of the human prostacyclin receptor with the PDZ adapter protein PDZK1: role in endothelial cell migration and angiogenesis

  2011cites this paper
• Vascular endothelial growth factor receptor-2 in breast cancer.

  2010cites this paper
• PPARα Is Essential for Microparticle-Induced Differentiation of Mouse Bone Marrow-Derived Endothelial Progenitor Cells and Angiogenesis

  2010cites this paper
• Molecular Cancer Antineoplastic Effect of Iodine in Mammary Cancer: Participation of 6-iodolactone (6-il) and Peroxisome Proliferator-activated Receptors (ppar)

  2009cites this paper
• Prostacyclin Inhibits IFN-γ-Stimulated Cytokine Expression by Reduced Recruitment of CBP/p300 to STAT1 in a SOCS-1-Independent Manner1

  2009cites this paper
• Recruitment of CBP / p 300 to STAT 1 in a Cytokine Expression by Reduced-Stimulated γ Prostacyclin Inhibits IFN -

  2009cites this paper
• Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes

  2009cites this paper
• Endothelial progenitor cells and angiogenesis join the PPARty.

  2008cites this paper